Ä¢¹½ÊÓƵAPP

Amanda Kay is Senior Partner and Chief Business Development Officer at Ä¢¹½ÊÓƵAPP. She joined Flagship in 2023 and today leads a team charged with forming platform and asset-based partnerships that help companies across the Flagship ecosystem realize the full potential of their technology. She is also instrumental in the architecture and implementation of the Innovation Supply Chain deals with leading pharmaceutical companies to source a pipeline of innovation from throughout Flagship’s 40+ companies.

A biologist by training, Amanda brings broad experience from pharmaceutical and biotechnology companies in business development, strategy, operations, and financial planning, together with a passion for working with scientists to translate innovative drug platform technologies into products that address unmet patient need.

Prior to joining Ä¢¹½ÊÓƵAPP, Amanda was Chief Business Officer and Head of Finance at Deep Genomics and Senior Vice President of Corporate Development at Synlogic, Inc., where she led a span of business functions including business development, investor relations, corporate strategy, alliance management, and new product commercialization efforts for these innovative drug discovery platform companies. She played a key role in defining the companies’ strategy, leading to both strategic biopharma transactions, financings, and Synlogic’s public launch.

Prior to joining Synlogic, Amanda served as Chief Operating Officer for Pfizer’s Inflammation and Immunology Research Unit and was a strategic lead on the marketing team for transplant and oncology products at Genzyme. She began her business career at L.E.K. Consulting, where she led more than fifty engagements, with clients ranging from start-ups to pharmaceutical companies.

Amanda received her B.A. in bacteriology from the University of Wisconsin, Madison, graduating both summa cum laude and Phi Beta Kappa. She received her Ph.D. in biology from Harvard University.